Transthyretin Cardiac Amyloid: 'Dr RR Baliga's "Got Knowledge Doc" Podcasts
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Release Date: 02/07/2024
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
The POPular PAUSE TAVI trial investigated whether continuing or interrupting oral anticoagulation during transcatheter aortic valve implantation (TAVI) affected clinical outcomes. The randomized, open-label, noninferiority study included 858 patients and assessed a composite primary outcome of cardiovascular death, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. The trial found that continuation was not noninferior to interruption, with higher bleeding risk but no significant difference in thromboembolic events, supporting interruption of...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
The six orthodox Indian schools of philosophy—Nyaya, Vaisheshika, Samkhya, Yoga, Mimamsa, and Vedanta—offer valuable insights into the mind-body connection, ethics, logic, and holistic well-being. Understanding these systems can benefit healthcare providers and patients in promoting mental, emotional, and physical health.
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
The TCW Trial compared TAVI + FFR-guided PCI versus SAVR + CABG in patients with severe aortic stenosis and complex coronary artery disease. This multicenter, randomized controlled trial included 172 patients aged ≥70 years. At 1 year, the primary composite endpoint (death, MI, stroke, revascularization, valve reintervention, or major bleeding) was significantly lower in the TAVI + PCI group (4%) compared to SAVR + CABG (23%), meeting both noninferiority and superiority criteria. The study suggests TAVI + PCI as a safer, less invasive alternative with reduced mortality and bleeding...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
đźš‘ New studies on #OHCA: No significant survival benefit of intraosseous (IO) over IV access. IV remains the preferred route, with IO as backup. #EmergencyMedicine #CPR #CardiacArrest These 2 randomized clinical trials compared intraosseous (IO) vs. IV vascular access in out-of-hospital cardiac arrest (OHCA). The first study (Denmark) found no significant difference in return of spontaneous circulation (ROSC), 30-day survival, or neurological outcomes between IO and IV access. The second study (UK) showed slightly higher ROSC in the IV-first group but no survival advantage. Both...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New study: Evolocumab shows strong CV benefits in older adults (≥75 yrs) with ASCVD! 📉 Lower LDL-C, reduced events (HR: 0.79, NNT: 19), & no major safety concerns. Time to rethink lipid guidelines for seniors? 🔬💙 #Cardiology #LipidLowering #Evolocumab
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Traditional lipid-lowering therapies have minimal impact on Lp(a), necessitating novel treatments. Zerlasiran, a small-interfering RNA (siRNA), significantly reduces Lp(a) (~85%) by inhibiting hepatic apolipoprotein(a) synthesis via subcutaneous injection. Muvalaplin, an oral small-molecule inhibitor, prevents Lp(a) particle formation, reducing levels by up to 85.8%. Both drugs were well-tolerated in Phase 2 trials, with further studies needed to...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
1. NEJM Article (2024): A 30-year study of 27,939 U.S. women found that high-sensitivity CRP, LDL cholesterol, and lipoprotein(a) independently predicted cardiovascular risk. Higher levels of these biomarkers increased the risk of major cardiovascular events, emphasizing the need for early screening and prevention in women. 2. BrJSportsMed Article (2024): A study of 13,018 women found that even 1–3 minutes/day of vigorous intermittent lifestyle physical activity (VILPA) significantly reduced cardiovascular risk. Women engaging in 3.4 minutes/day had a 45% lower MACE risk and 67% lower heart...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
1. “Bioaccumulation of Microplastics in Decedent Human Brains” (Nature Medicine, 2024) This study confirms the presence of microplastics and nanoplastics (MNPs) in human brain tissue, particularly the frontal cortex. Researchers used pyrolysis gas chromatography-mass spectrometry (Py-GC/MS) and electron microscopy to analyze postmortem samples, finding polyethylene (PE) as the dominant plastic type. Brain tissue exhibited significantly higher plastic concentrations than the liver or kidney, with even greater MNP accumulation in individuals diagnosed with dementia. The findings raise...
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Kapila: Founder of Samkhya Philosophy Kapila (7th–6th century BCE) is regarded as the founder of the Samkhya school, one of the six orthodox systems of Hindu philosophy. Known for his rational and dualistic approach, he emphasized the distinction between Purusha (consciousness) and Prakriti (matter). His teachings are captured in the Samkhya Sutras and the Bhagavata Purana, where he elaborated on metaphysics, self-realization, and liberation from suffering. Kapila’s influence extends to Hinduism, Buddhism, and Jainism, making him a pivotal figure in ancient Indian philosophy.
info_outlineDr. Baliga's 'Got Knowledge Doc?' PODKASTS
Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT- HEART randomised controlled trial in Scotland Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators* Summary Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography...
info_outline🎧 Transthyretin (TTR) Amyloid: Dr RR Baliga "Got Knowledge Doc" PodKast for Physicians
1. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry Scott M. Damrauer, MD; Kumardeep Chaudhary, PhD; Judy H. Cho, MD; et al. JAMA. Dec10th, 2019;322(22):2191-2202. doi:10.1001/jama.2019.17935
2. Treatment of Cardiac Transthyretin Amyloidosis: Emdin M, Aimo A, Rapezzi C, et al. An Update. Eur Heart J 2019;40:3699-3706.
3. Treatment of Cardiac Transthyretin Amyloidosis Dec 13, 2019 | RR. Baliga, MD, FACC
Transthyretin (TTR) Amyloid: "Hot-off-the-Press Dr RR Baliga MUST KNOW FACTS PodKast"
1. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry Scott M. Damrauer, MD; Kumardeep Chaudhary, PhD; Judy H. Cho, MD; et al. JAMA. Dec10th, 2019;322(22):2191-2202. doi:10.1001/jama.2019.17935
2. Treatment of Cardiac Transthyretin Amyloidosis: An Update. Eur Heart J 2019;40:3699-3706.
3. Treatment of Cardiac Transthyretin Amyloidosis Dec 13, 2019 | RR. Baliga, MD, FACC